KR20030091952A - 선택적인 암 치료용의 특이적 인간 항체 - Google Patents

선택적인 암 치료용의 특이적 인간 항체 Download PDF

Info

Publication number
KR20030091952A
KR20030091952A KR10-2003-7008885A KR20037008885A KR20030091952A KR 20030091952 A KR20030091952 A KR 20030091952A KR 20037008885 A KR20037008885 A KR 20037008885A KR 20030091952 A KR20030091952 A KR 20030091952A
Authority
KR
South Korea
Prior art keywords
polypeptide
peptide
seq
cell
amino acid
Prior art date
Application number
KR10-2003-7008885A
Other languages
English (en)
Korean (ko)
Inventor
하가이요체베드
라자로비츠자넷
거이라첼
립쉬츠올리
스잔톤이스터
레바논아비그도
플락신대니얼
페레츠투비아
Original Assignee
사비언트 파마슈티컬즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사비언트 파마슈티컬즈 인코퍼레이티드 filed Critical 사비언트 파마슈티컬즈 인코퍼레이티드
Publication of KR20030091952A publication Critical patent/KR20030091952A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR10-2003-7008885A 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체 KR20030091952A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
KR20030091952A true KR20030091952A (ko) 2003-12-03

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7008885A KR20030091952A (ko) 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체

Country Status (15)

Country Link
EP (1) EP1353937A4 (zh)
JP (1) JP2004524023A (zh)
KR (1) KR20030091952A (zh)
CN (1) CN100374456C (zh)
AU (1) AU2002246737B2 (zh)
BR (1) BR0116763A (zh)
CA (1) CA2433227A1 (zh)
CZ (1) CZ20031983A3 (zh)
HU (1) HUP0400775A2 (zh)
IL (1) IL156690A0 (zh)
MX (1) MXPA03005944A (zh)
NZ (1) NZ527173A (zh)
PL (1) PL365758A1 (zh)
RU (1) RU2316564C2 (zh)
WO (1) WO2002059264A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279657A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
EP2373343B1 (en) * 2008-12-19 2015-02-11 Philogen S.p.A. Immunocytokines for tumour therapy with chemotherapeutic agents
MY161679A (en) * 2010-07-09 2017-05-15 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
US9695234B2 (en) * 2014-10-23 2017-07-04 Singh Molecular Medicine, Llc Single domain antibodies directed against STAT3
WO2016100533A2 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108290940B (zh) * 2015-10-01 2021-12-07 圣拉斐尔医院有限公司 Tcr及其用途
WO2017087789A1 (en) * 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CR20220408A (es) * 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
EP4244251A1 (en) * 2020-11-13 2023-09-20 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
EP1353937A2 (en) 2003-10-22
WO2002059264A3 (en) 2003-03-06
EP1353937A4 (en) 2005-04-13
MXPA03005944A (es) 2005-04-29
CA2433227A1 (en) 2002-08-01
PL365758A1 (en) 2005-01-10
CZ20031983A3 (cs) 2005-07-13
BR0116763A (pt) 2004-03-09
CN1551886A (zh) 2004-12-01
NZ527173A (en) 2006-03-31
WO2002059264A2 (en) 2002-08-01
HUP0400775A2 (en) 2007-05-02
IL156690A0 (en) 2004-01-04
JP2004524023A (ja) 2004-08-12
RU2003123100A (ru) 2005-03-10
RU2316564C2 (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20090220486A1 (en) Antibodies and uses thereof
EP1268800A2 (en) Mucin-1 specific binding members and methods of use thereof
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
MXPA03005945A (es) Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos.
JP2005503756A5 (zh)
US20040202665A1 (en) Compositions and methods for therapeutic treatment
CA2491363A1 (en) Antibodies and uses thereof
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
JP2007528711A (ja) 抗体及びその使用
US20040208877A1 (en) Antibodies and uses thereof
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
KR20240148849A (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application